Combining ICOVIR17 with PD-1 blockade antibodies induces tumor-associated pro-inflammatory macrophages and tumor-specific T cell cytotoxicity locally and systemically, enhancing tumor killing and further extending the survival of GBM mice [446]. Here, PDCD1 is linked to neoplasm.